How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,537 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Amyloid A amyloidosis secondary to hyper IgD syndrome and response to IL-1 blockage therapy. (Abstract)

Amyloid A amyloidosis secondary to hyper IgD syndrome and response to IL-1 blockage therapy. A 62-year-old woman with a history of genetically confirmed hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS) was admitted because of chronic diarrhoea. During admission she developed a rapidly progressive nephrotic syndrome. Reactive amyloid A (AA) amyloidosis was confirmed after colonic and renal biopsy which showed deposition of amyloid. After initial treatment with high-dosed (...) corticosteroids, therapy was switched to anakinra, an IL-1 receptor antagonist, but her symptoms persisted. After cessation of anakinra, a marked exacerbation of the intestinal symptoms was noted. Nine months after the initial diagnosis of reactive amyloidosis without any amelioration of the symptoms and a decreasing quality of life, our patient declined further treatment and died soon after. This case demonstrates that AA amyloidosis does occur in patients with HIDS and can present with intestinal symptoms

2016 Netherlands Journal of Medicine

122. Long-Term Medical Management of the Pediatric Patient After Liver Transplantation

outcomes have not been de?ned. 188,189 With stage 3 or greater chronic kidney disease, a reduction of CNI exposure may have limited utility. There are insuf?cient data to support the com- plete withdrawal of immunosuppressive medications. Recommendation 25. Regularly screen renal function with the eGFR and practice calcineurin minimization. Consider renal-sparing drugs when the calculated GFR is 5 years, cholestatic liver disease other than biliary atresia, Hispanic race, early use of corticosteroids (...) and varies among centers. A proposed alternative entails a short course of chemoprophylaxis with intravenous ganciclovir followed by serial monitoring of the CMV load to inform the use of secondary preemptive ther- apy. 254,255 The low incidence of CMV disease in donor- negative/recipient-negative recipients limits the neces- sity for prophylaxis or monitoring in this population. Treatment. Ganciclovir dramatically improves out- comes; intravenous ganciclovir is recommended as the initial therapy. Oral

2013 American Association for the Study of Liver Diseases

123. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient

Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient Guidelines for the Provision and Assessment of Nutrition Sup... : Critical Care Medicine You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page. Login No user account? Lippincott Journals Subscribers , use your username or email along with your password to log in. Remember me on this computer Register for a free account (...) my selection doi: 10.1097/CCM.0000000000001525 Special Article Free Supplemental Digital Content is available in the text. 1 Nutrition Support Specialist, Barnes Jewish Hospital, St. Louis, MO. 2 Department of Medicine, University of Louisville, Louisville, KY. 3 Chief Division of General Surgery, Oregon Health and Science University, Portland, OR. 4 Critical Care Dietitian, Portland VA Medical Center, Portland, OR. 5 Clinical Nurse Specialist: Wound, Skin, Ostomy, UW Health University

2016 Society of Critical Care Medicine

124. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient

and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Volume 40 Issue 8 Journal of Parenteral and Enteral Nutrition pages: 1200-1200 First Published online: September 15, 2016 Corresponding Author E-mail address: Department of Medicine, University of Louisville, Louisville, Kentucky Beth Taylor and Steven McClave are co–first authors of this article. Stephen A. McClave, MD (...) , Department of Medicine, University of Louisville, Louisville, KY. Email: Charlene Compher, RD, PhD, Professor of Nutrition Science, University of Pennsylvania School of Nursing, Philadelphia, PA, USA. Email: Nutrition Support Specialist, Barnes Jewish Hospital, St Louis, Missouri Beth Taylor and Steven McClave are co–first authors of this article. Chief Division of General Surgery, Oregon Health and Science University, Portland, Oregon Critical Care Dietitian, Portland VA Medical Center, Portland, Oregon

2016 American Society for Parenteral and Enteral Nutrition

125. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications Full Text available with Trip Pro

, mural, infection, diagnosis, bacteremia, case definition, epidemiology, risks, demographics, injection drug use, echocardiography, microbiology, culture-negative, therapy, antibiotic, antifungal, antimicrobial, antimicrobial resistance, adverse drug effects, drug monitoring, outcome, meta-analysis, complications, abscess, heart failure, embolic events, stroke, conduction abnormalities, survival, pathogens, organisms, treatment, surgery, indications, valve replacement, valve repair, ambulatory care (...) events during first 2 wk of antimicrobial therapy Increase in vegetation size despite appropriate antimicrobial therapy Valvular dysfunction Acute aortic or mitral insufficiency with signs of ventricular failure Heart failure unresponsive to medical therapy Valve perforation or rupture Perivalvular extension Valvular dehiscence, rupture, or fistula New heart block Large abscess or extension of abscess despite appropriate antimicrobial therapy See text for a more complete discussion of indications

2016 Infectious Diseases Society of America

126. Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

/ by David Kinnison on 11/09/2012e4S Immunosuppressive Drugs in Lung Disease and Lung Transplant Patients disease and for lung transplant recipients. Early rec- ognition of conditions that require immunosuppressive therapy and prompt administration of immunosup- pressive agents can prevent or minimize tissue injury and prevent irreversible decline in organ function. Because these medications can be harmful, timely detection and remediation of clinically signi? cant side effects can improve the bene? t (...) Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients CHEST Evidence-Based Medicine journal.publications.chestnet.org CHEST / 142 / 5 / NOVEMBER 2012 e1S 3.1 Anti-Tumor Necrosis Factor- a (TNF- a ) Agents Objectives: Immunosuppressive pharmacologic agents prescribed to patients with diffuse inter- stitial and in? ammatory lung disease and lung transplant recipients are associated with poten- tial risks for adverse reactions. Strategies

2012 American College of Chest Physicians

127. CRACKCast E144 – High Altitude Medicine

oxygen at rest and with mild exercise. Re-ascent with pulmonary vasodilator medication may be considered. Other prevention therapies: PDE5 inhibitors Dexamethasone Salmeterol Acetazolamide (to help with acclimatization, prevent HAPE, and reduce pulmonary vasoconstriction) [8] How do you treat HACE? HACE is the least common but most severe form of high-altitude illness. Death from HACE at as low as 2500m is reported, although most cases occur above 3000m. Mild AMS can progress to severe HACE with coma (...) volume and pressure, which may play an additional role in its therapeutic effect. In addition, it has positive effects beyond its role as a carbonic anhydrase inhibitor, with beneficial chemoreceptor effects on ventilatory drive, alterations of cerebral blood flow, relaxation of smooth muscles, and upregulation of fluid resorption in the lungs. Adverse reactions: Paresthesias Polyuria Nausea Diarrhea Drowsiness Tinnitus Myopia Change of taste in foods Sulfa medication cross reactivity WiseCracks [1

2018 CandiEM

128. Menopausal Symptoms: Comparative Effectiveness of Therapies

Women's Health Center, Massachusetts General Hospital Associate Professor of OB/Gyn and Reproductive Biology, Harvard Medical School Boston, MA Lynne Shuster, M.D., FACP Assistant Professor of Medicine Mayo Clinic Rochester, MN vi Menopausal Symptoms: Comparative Effectiveness of Therapies Structured Abstract Objectives. To systematically review and synthesize evidence evaluating the comparative effectiveness of treatments for menopausal symptoms, along with potential long-term benefits and harms (...) of those treatments. Data sources. The following electronic databases were searched through January 2014: MEDLINE ® , Embase ® , Cochrane Controlled Trials Register, and AMED Allied and Complementary Medicine. Gray literature searches included clinicaltrials.gov, the Food and Drug Administration Web site, and relevant conference abstracts. Review methods. Menopausal symptom outcomes included: vasomotor, quality of life, psychological, sexual function, urogenital, and sleep disturbance. Randomized

2015 Effective Health Care Program (AHRQ)

129. Study to Compare the Bioavailability (Amount of Drug Reaching the Blood) of Omeprazole 20 mg Before and After Undergoing Surgery for Morbid Obesity

Title: Bioavailability Study of Omeprazole (20 mg) at Steady State (Multiple Dose) in Patients Who Have Undergone Bariatric Surgery Actual Study Start Date : October 31, 2014 Actual Primary Completion Date : December 23, 2015 Actual Study Completion Date : February 29, 2016 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment omeprazole omeprazole 20 mg Drug: Omeprazole 20mg Outcome Measures Go to Primary (...) examination and laboratory analysis before inclusion in the study. Exclusion Criteria: Any postoperative complication that interferes with the regular intake of medication such as stenosis of anastomotic, fistula, persistent vomiting, diarrhea (> 4 stools per day), evidence of protein malnutrition (albumin <3.5 g / l). High consumption of stimulating beverages (equivalent to 400 mg of caffeine per day, a cup of coffee contains approximately 100 mg of caffeine). Consumption of any medication that may

2017 Clinical Trials

130. Clinical Studies by Using Accelerated PDX Model to Screen Drugs for Advanced Solid Tumor

in subjects with advanced malignant tumor. Condition or disease Intervention/treatment Phase Metastatic Cancer Drug: Non Chemotherapy Drug: Chemotherapy and target therapy Drug: Chinese herb medicine Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 50 participants Intervention Model: Single Group Assignment Intervention Model Description: This single center, open-label, single arm, non-randomized study is designed to evaluate (...) safety, progression-free survival(PFS),overall survival (OS), objective response rate (OPR), and disease control rate (DCR) of chemotherapy or target therapy or chinese medicine based on the Alphacait screening system in subjects with advanced malignant tumor. Masking: None (Open Label) Primary Purpose: Treatment Official Title: Clinical Studies by Using Alphacait to Screen Drug Combinations for Advanced Solid Tumor Actual Study Start Date : January 1, 2017 Estimated Primary Completion Date

2017 Clinical Trials

131. Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets

by (Responsible Party): Food and Drug Administration (FDA) Study Details Study Description Go to Brief Summary: The purpose of this study is to measure the amount of study drug present in blood after being administered a generic version of nifedipine extended-release tablets, 60 mg (Valeant Pharmaceuticals, LLC) and brand-name version PROCARDIA XL extended-release tablets, 60 mg (Pfizer Inc.) individually and in presence of stomach acid reducing drug (antacid), omeprazole/sodium bicarbonate capsules, 40 mg (...) gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel disease), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting, swallowing disorder), or other conditions known to interfere with the absorption, distribution, metabolism or excretion of the drug experienced within 7 days prior to first dosing, as determined by the PI/Sub-Investigator. QTc interval > 430 milliseconds for males and > 450 milliseconds for females, unless deemed otherwise by the PI/Sub-Investigator. Abnormal clinical

2017 Clinical Trials

132. Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers

study. Condition or disease Intervention/treatment Phase Aging Drug: Sirolimus Drug: Metformin Drug: Diclofenac Phase 1 Detailed Description: The primary endpoint of the study is the profile of differences in transcript levels of age-associated genes such as those in the lamin-A, insulin like growth factor (IGF) and NFKB pathways as well as noncoding RNAs in topical agent-exposed arm skin versus placebo exposed arm skin in healthy volunteers. The secondary endpoints include (1) differences in skin (...) (Participant, Outcomes Assessor) Primary Purpose: Basic Science Official Title: Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers Actual Study Start Date : March 1, 2017 Estimated Primary Completion Date : July 1, 2017 Estimated Study Completion Date : December 31, 2017 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Sirolimus, metformin, diclofenac

2017 Clinical Trials

133. Two, three, and four-drug regimens for HIV post-exposure prophylaxis in a North American sexual assault victim population. (Abstract)

effects (72.2% vs. 17.6%) in the later cohort. We subsequently compared all patients in either cohort who received four-drug therapy (N=128) versus those who received two or three-drug regimens (N=47). The two or three-drug regimen group had a higher completion rate (66.0% vs. 42.2%; p=0.03), and a lower rate of reported side effects (19.1% vs. 53.9%), specifically for nausea (12.8% vs. 36.7%), constipation (0% vs. 7.9%), diarrhea (2.1% vs. 21.1%), mood changes (0% vs. 10.9%), headache (2.1% vs. 16.4 (...) care facility before and after the introduction of two and three-drug post-exposure prophylaxis regimens. Our primary outcome was completion of the 28-day regimen. Secondary objectives included HIV seroconversion rates and patient reported side effects.Six-hundred-thirty charts from a 2-year period were reviewed, and 429 met inclusion criteria. There was no difference in completion rates of post-exposure prophylaxis between the two cohorts (50.5% vs. 51.6%). However, there were fewer reported side

2017 American Journal of Emergency Medicine

134. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. Full Text available with Trip Pro

in a single-arm, multicenter trial in patients with relapsed/refractory metastatic TNBC who received a 10 mg/kg starting dose on days 1 and 8 of 21-day repeated cycles. The primary end points were safety and objective response rate; secondary end points were progression-free survival and overall survival. Results In 69 patients who received a median of five prior therapies (range, one to 12) since diagnosis, the confirmed objective response rate was 30% (partial response, n = 19; complete response, n = 2 (...) Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug conjugate, targets Trop-2 for the selective delivery of SN-38, the active metabolite of irinotecan. Patients and Methods We evaluated sacituzumab govitecan

2017 Journal of Clinical Oncology

135. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. Full Text available with Trip Pro

escalating from 0.15 to 7.0 mg/kg. No meaningful drug accumulation was observed with the dosing regimen of once every 3 weeks. The most common treatment-related adverse events were fatigue, blurred vision, and diarrhea, the majority of which were grade 1 or 2. The dose-limiting toxicities observed were grade 3 hypophosphatemia (5.0 mg/kg) and grade 3 punctate keratitis (7.0 mg/kg). Two patients, both of whom were individuals with epithelial ovarian cancer, achieved confirmed tumor responses according (...) Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate that selectively targets folate receptor α (FRα). In this phase 1 dose-escalation study, the authors investigated IMGN853 in patients with FRα-positive solid tumors.Patients received IMGN853 on day 1 of a 21-day cycle (once every 3 weeks dosing), with cycles repeated until

2017 Cancer

136. Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial. Full Text available with Trip Pro

ondansetron (dose titrated up to 24 mg daily) or placebo for 12 weeks. Throughout the trial, participants will record their worst abdominal pain, worst urgency, stool frequency, and stool consistency on a daily basis. The primary endpoint is the proportion of "responders" in each group, using Food and Drug Administration (FDA) recommendations. Secondary endpoints include pain intensity, stool consistency, frequency, and urgency. Mood and quality of life will also be assessed. Mechanistic assessments (...) Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial. Irritable bowel syndrome with diarrhoea (IBS-D) affects up to 4% of the general population. Symptoms include frequent, loose, or watery stools with associated urgency, resulting in marked reduction of quality of life and loss of work productivity. Ondansetron, a 5HT3 receptor antagonist, has had an excellent safety record for over 20 years as an antiemetic

2019 Trials Controlled trial quality: predicted high

137. Evaluating respiratory cryptosporidiosis in pediatric diarrheal disease: protocol for a prospective, observational study in Malawi. Full Text available with Trip Pro

Evaluating respiratory cryptosporidiosis in pediatric diarrheal disease: protocol for a prospective, observational study in Malawi. Cryptosporidium is among the most common causes of severe diarrhea in African children 0-23 months old. It is associated with excess mortality, stunting and malnutrition. The most common manifestation of cryptosporidium is intestinal diarrheal disease. However, respiratory cryptosporidiosis has been documented in up to a third of children presenting with diarrhea (...) . It is unclear whether respiratory involvement is a transient phenomenon or a reservoir for gastrointestinal (GI) disease. This study aims to evaluate the role of respiratory cryptosporidiosis in pediatric diarrheal disease.This is a prospective, observational study conducted at Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi. Young children aged 2-24 months hospitalized with diarrhea will be enrolled. Enrolled children will have induced sputum, nasopharyngeal (NP) swab and stool samples

2019 BMC Infectious Diseases

138. A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Bacillus coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort. (Abstract)

of abdominal pain, time to complete resolution of abdominal discomfort, complete remission of diarrhea, and quality of life (QoL). The secondary outcomes were physical examination and vitals, hematological analysis, and assessment of reported adverse events (AEs) or serious adverse events (SAEs).Trial data showed that the LAB was well-tolerated by participants at the dose provided. The LAB was effective in recovering from acute diarrhea with abdominal pain and discomforts and exhibited improved cluster (...) of QoL. No AEs or SAEs were reported during the trial.It is evident that the test drug, i.e., LAB (B. coagulans strain LBSC) is safe and effective for improving the pathophysiological conditions related to acute diarrhea and abdominal discomfort evaluated through stage-II clinical trial.

2019 European journal of clinical pharmacology Controlled trial quality: predicted high

139. Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial. Full Text available with Trip Pro

-controlled, randomized phase III trial involving community-based and academic institutions in 40 countries. Women with HER2-positive early-stage breast cancer with prior standard primary therapy and trastuzumab-based (neo)adjuvant therapy were randomized to neratinib 240 mg/day or placebo for 12 months. Safety, a secondary outcome, was assessed using the National Cancer Institute Common Terminology Criteria version 3.0. Health-related quality of life by diarrhea grade was assessed using Functional (...) Assessment of Cancer Therapy-Breast (FACT-B).Two thousand eight hundred sixteen women (1408 per group) were safety-evaluable. Grade 3 and 4 diarrhea occurred in 561 (39.8%) and 1 (0.1%) patients with neratinib versus 23 (1.6%) and 0 patients with placebo, respectively. In the neratinib group, 28.6% of patients had grade 3 events during month 1 decreasing to ≤ 6% after month 3. The median cumulative duration of grade 3/4 diarrhea with neratinib was 5 days (interquartile range, 2-9). Serious diarrheal

2019 Breast cancer research : BCR Controlled trial quality: predicted high

140. Blood Test for Early Detection of Breast Cancer Using Todos Medical -Breast 1(TM-B1) Assay

Detection of Breast Cancer Using Todos Medical -Breast 1(TM-B1) Assay Actual Study Start Date : January 22, 2018 Estimated Primary Completion Date : May 1, 2019 Estimated Study Completion Date : July 1, 2019 Resource links provided by the National Library of Medicine related topics: related topics: Groups and Cohorts Go to Group/Cohort Intervention/treatment Screening Population Cohort 1:Screening Population - Women presenting for routine XRM and / or breast US. Participants will be followed for one (...) , diarrhea, headache, vomiting, dizziness etc. Subject is pregnant, lactating, or undergoing fertility treatment. Subject has participated in this study, in another cohort, and the TM-B1 test was performed. Breast Cancer Population only: The subject's tumor has been surgically removed before sample collection for TM-B1 analysis. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>